Legislation has been introduced in the State Assembly and Senate of New York (AB 158 and SB 58) that would limit the ability of PBMs to manage drug benefits for health plans. The Pharmaceutical Care Management Association engaged PricewaterhouseCoopers to estimate the impact of certain provisions of the legislation that would require PBMs to disclose proprietary contract terms and pricing data.